Proactive Investors - Run By Investors For Investors

Pharmas Regeneron and Teva shares hit by FDA order

Shares of Regeneron Pharmaceuticals and Teva Pharmaceuticals were hit Monday by news of a clinical trial setback for a new pain drug they are co-developing
Pharmas Regeneron and Teva shares hit by FDA order
Investors endure back pain from FDA ruling

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) and Teva Pharmaceuticals (NYSE:TEVA) were hit Monday by news of a clinical trial setback for a new pain drug they are co-developing.

US regulators put on hold a clinical trial involving an experimental treatment for chronic low back pain due to safety concerns. Regeneron shares closed down 1.3% at $366.73.

Teva, which is collaborating on the drug, saw its US-listed shares drop during the session although the managed to repair the damage and ended flat at $41.80.

The US Food and Drug Administration had ordered the hold and told Regeneron and Teva to amend the study protocol after observing a case of adjudicated arthropathy – a type of joint disease – in one patient who had osteoarthritis. As a result, Regeneron said it had stopped dosing study patients and was working to design a new study phase that excludes patients with osteoarthritis.

The drug, fasinumab, aims to offer treatment for millions of Americans who suffer from chronic low back pain and osteoarthritis without the use of highly addictive opioids, by targeting proteins that grow nerve cells. Rivals Eli Lilly (NYSE:LLY) and Pfizer (NYSE:PFE) are racing to develop a similar drug, tanezumab, which aims to treat osteoarthritis, back pain and cancer pain, which they aim to submit for approval by 2018.

View full TEVA profile View Profile

Teva Pharmaceutical Industries Timeline

Related Articles

March 15 2018
Amryt's lead drug candidate, AP101, is a potential treatment for epidermolysis bullosa, a rare genetic skin disorder for which there is currently no approved treatment
Vial of pills
May 17 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
picture of cannabis plants
March 23 2018
Control of the supply chain offers operational advantages and financial benefits.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use